Alnylam Pharmaceuticals (ALNY) : Rtw Investments scooped up 303,682 additional shares in Alnylam Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 866,379 shares of Alnylam Pharmaceuticals which is valued at $45.5 Million.Alnylam Pharmaceuticals makes up approximately 18.26% of Rtw Investments’s portfolio.
Other Hedge Funds, Including , Sumitomo Mitsui Asset Management Company Ltd boosted its stake in ALNY in the latest quarter, The investment management firm added 49 additional shares and now holds a total of 5,124 shares of Alnylam Pharmaceuticals which is valued at $269,266. Alnylam Pharmaceuticals makes up approx 0.01% of Sumitomo Mitsui Asset Management Company Ltd’s portfolio. Parametrica Management Ltd added ALNY to its portfolio by purchasing 3,259 company shares during the most recent quarter which is valued at $181,037. Alnylam Pharmaceuticals makes up approx 0.65% of Parametrica Management Ltd’s portfolio.Kornitzer Capital Management Inc Ks boosted its stake in ALNY in the latest quarter, The investment management firm added 19,010 additional shares and now holds a total of 110,160 shares of Alnylam Pharmaceuticals which is valued at $6.1 Million. Alnylam Pharmaceuticals makes up approx 0.11% of Kornitzer Capital Management Inc Ks’s portfolio. Capital Fund Management S.a. added ALNY to its portfolio by purchasing 59,450 company shares during the most recent quarter which is valued at $3.3 Million. Alnylam Pharmaceuticals makes up approx 0.06% of Capital Fund Management S.a.’s portfolio. Tarbox Group added ALNY to its portfolio by purchasing 10 company shares during the most recent quarter which is valued at $670.
Alnylam Pharmaceuticals opened for trading at $54.01 and hit $55.63 on the upside on Monday, eventually ending the session at $54.54, with a gain of 3.79% or 1.99 points. The heightened volatility saw the trading volume jump to 7,85,434 shares. Company has a market cap of $4,666 M.
On the company’s financial health, Alnylam Pharmaceuticals reported $-1.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on May 2, 2016. Analyst had a consensus of $-1.09. The company had revenue of $7.35 million for the quarter, compared to analysts expectations of $7.74 million. The company’s revenue was down -60.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.62 EPS.
Many Wall Street Analysts have commented on Alnylam Pharmaceuticals. Chardan Capital Markets Initiated Alnylam Pharmaceuticals on Apr 5, 2016 to “Buy”, Price Target of the shares are set at $93.Alnylam Pharmaceuticals was Upgraded by JP Morgan to ” Overweight” on Mar 11, 2016. Shares were Reiterated by Leerink Partners on Feb 16, 2016 to “Outperform” and Lowered the Price Target to $ 120 from a previous price target of $152 .
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease with a pipeline of RNAi therapeutics toward genetically validated liver-expressed disease in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-GO1 ALN-TMP ALN-PCS ALN-PCSsc ALN-AC3 ALN-ANG ANGPTL3 ALN-HBV ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.